Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Summit inks breakthrough Seglin deal with Bristol-Myers Squibb

  Summit Corp this morning unveiled a collaboration with one of the world’s largest pharmaceuticals companies that could eventually be worth US$30 million per product in research, development and regulatory milestone payments.  
Summit inks breakthrough Seglin deal with Bristol-Myers Squibb

 

Summit Corp (LON:SUMM) this morning unveiled a collaboration with one of the world’s largest pharmaceuticals companies that could eventually be worth US$30 million per product in research, development and regulatory milestone payments.

Initially Bristol-Myers Squibb will pay US$100,000 fee to access the company’s Seglin technology.

It is hoped these second generation immunosugars will provide a radical new platform to develop drugs for illnesses such as Alzheimers. 

The importance of proteins and nucleic acids is well established in drug discovery, but the targeting of carbohydrate biology remains largely underexploited.  Seglin technology hopes to redress the balance. 

The partnership is an early first step in the re-focused strategy set out by chief executive Glyn Edwards.

Last week he revealed he wanted “someone else to pick up the heavy lifting” on the exciting Seglin programme, which is still in the very early phase of development, to allow the company to focus on their two key drug candidates.

In C1100, the group has a potentially breakthrough treatment for Duchenne Muscular Dystrophy. Its second major discovert, SMT 19969, is a highly potent anti-biotic designed to tackle the hospital superbug C.difficile.

Edwards said this morning: “This agreement with Bristol-Myers Squibb further reinforces our strategy as we seek alternative ways to realise the value of our Seglin technology while we concentrate our resources on advancing our core Duchenne Muscular Dystrophy and C. difficile programmes.”

Under the terms of the agreement, Bristol-Myers will be responsible for the discovery stage research and will have the exclusive right to develop and commercialise any Seglin products that are identified.

The AIM listed group will receive afore mentioned technology access fee and is eligible for research, development and regulatory milestones of up to $30 million per product, plus royalties on worldwide sales of any products. 


 

Ian_55ae0ddd437b7.jpg
Why Invest In Summit Therapeutics PLC? Read More Here

Register here to be notified of future SUMM Company articles
View full SUMM profile

Summit Therapeutics PLC Timeline

Related Articles

Knee surgery
October 12 2016
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.
viagra2.jpg
September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.
World map made out of drugs
November 07 2016
The pharma services and drug development group has hit key milestones in the last year.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.